Elecsys hiv combi pt

Manufactured by Roche

Sourced in Germany

The Elecsys HIV combi PT is a laboratory instrument used for the detection of human immunodeficiency virus (HIV) antibodies and p24 antigen. It is designed to provide accurate and reliable results for the diagnosis of HIV infection.

Automatically generated - may contain errors

Lab products found in correlation

Architect hiv ag ab combo, by Abbott (2 mentions) Cobas e411, by Roche (1 mentions) Canto 2 flow cytometer, by BD (1 mentions) Genscreen hiv 1 2 antibody eia, by Bio-Rad (1 mentions) Inno lia hiv 1 2 score, by Fujirebio (1 mentions) Vca igg, by DiaSorin (1 mentions) Cmia sars cov 2 igg assay, by Abbott (1 mentions) Hiv ag ab combo, by Abbott (1 mentions) Elecsys anti hcv 2, by Roche (1 mentions) Elecsys anti hbc 2, by Roche (1 mentions) Elecsys hbsag 2, by Roche (1 mentions) Cobas 6000, by Roche (1 mentions) Cobas ampliprep cobas taqman hcv test, by Roche (1 mentions)

5 protocols using elecsys hiv combi pt

Automated HIV Screening with Cobas E 411

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cobas E 411 (Roche Diagnostics GmbH, Mannheim, Germany) is a fully automated immunoassay analyzer which uses electro-chem-iluminescence immunoassay (ECLIA) technology to detect HIV-1 and HIV-2 in human serum. The analyzer had sample loading chambers, a touch-screen monitor and a printer. This study used Elecsys HIV combi PT (Roche Diagnostics GmbH, Mannheim, Germany) as reagents. This reagent is a fourth generation qualitative immunoassay for the determination of HIV-1 p24 antigens and antibodies to HIV-1, including group O, and HIV-2 in serum. Test results were produced within 30 min after loading samples.
Samples with cutoff index (COI) <0.9 were considered non-reactive (negative) and those with COI ≥1.0 considered reactive (positive). There were no observed COI readings in the range ≥0.9 to <1.0 (borderline) among the samples, HIV RNA test was therefore not needed.

Boadu R., Darko G., Nortey P., Akweongo P, & Sarfo B. (2016). Assessing the sensitivity and specificity of First Response HIV-1-2 test kit with whole blood and serum samples: a cross-sectional study. AIDS Research and Therapy, 13, 9.

+ Open protocol

+ Expand

Validation of HIV Rapid Diagnostic Tests

Check if the same lab product or an alternative is used in the 5 most similar protocols

DHC results were classified as true or false with reference to results of the laboratory assays which are standard of care in this setting: fourth generation HIV screening immunoassay (Architect HIV Ag/Ab Combo, Abbott Diagnostics, Wiesbaden, Germany; or Elecsys HIV Combi PT, Roche Diagnostics, Mannheim, Germany), supplementary HIV antibody (Serodia HIV-1 Antibody particle agglutination assay, Fujirebio, Tokyo, Japan; or Genscreen HIV 1&2 Antibody EIA, Bio-Rad Laboratories, Redmond, WA), HIV p24 antigen immunoassay (Genscreen HIV-1 p24 Antigen, Bio-Rad Laboratories, Redmond, WA) and HIV Western blot (HIV Western Blot 2.2, MP Diagnostics, Singapore). In men diagnosed HIV-positive, HIV RNA (HIV Cobas Taqman 48 v2.0, Roche Diagnostics, Branchburg, NJ), CD4 T-cell count (Canto II flow cytometer, Becton Dickenson, San Jose, CA) and genotype (Vircotype HIV-1, Janssen Diagnostics, Beerse, Belgium) tests were performed.

Conway D.P., Holt M., McNulty A., Couldwell D.L., Smith D.E., Davies S.C., Cunningham P., Keen P, & Guy R. (2014). Multi-Centre Evaluation of the Determine HIV Combo Assay when Used for Point of Care Testing in a High Risk Clinic-Based Population. PLoS ONE, 9(4), e94062.

+ Open protocol

+ Expand

Comprehensive Diagnostic Assays for Viral Infections

Check if the same lab product or an alternative is used in the 5 most similar protocols

Blood counts were determined at the Central Laboratory of the University Hospital Essen according to routine procedures. For HIV-1/2 diagnostics, the screening tests Architect HIV Ag/Ab Combo (chemiluminescent microparticle immunoassay (CMIA); Abbott, Wiesbaden, Germany) and Elecsys HIV combi PT (electrochemiluminescence immunoassay; Roche Diagnostics, Rotkreuz, Switzerland) were utilized. Further, the confirmatory test INNO-LIA HIV I/II Score (line-immunoassay; Fujirebio, Hannover, Germany) and RealTime HIV-1 m2000sp (qPCR; Abbott, Wiesbaden, Germany) were employed. The presence of an EBV infection was assessed using the chemiluminescence immunoassays (CLIAs) Liaison EBV IgM, VCA IgG, and EBNA IgG (all DiaSorin, Dietzenbach, Germany). SARS-CoV-2-specific Abs were measured using the SARS-CoV-2 S1/S2 IgG ELISA (DiaSorin) and the CLIA Liaison SARS-CoV-2 TrimericS IgG assay (DiaSorin) for spike-specific Abs (IgG S), while the CMIA SARS-CoV-2 IgG assay (Abbott) was used for nucleocapsid (N)-specific Abs (IgG N).

Elsner C., Appeltrath G.A., Konik M., Parreuter J., Broecker-Preuss M., Krawczyk A., Esser S., Sammet S, & Karsten C.B. (2023). False-Positive Screening and Confirmatory HIV Diagnostic Test in a Patient with Cured SARS-CoV-2 Infection Is Not Mediated by Env/Spike Cross-Reactive Antibodies. Viruses, 15(5), 1161.

+ Open protocol

+ Expand

Multimodal Hepatitis Infection Screening

Check if the same lab product or an alternative is used in the 5 most similar protocols

All serum samples were tested for HBsAg, anti‐HCV, and anti‐HIV using the CLIA on the Cobas® 6000 analyzer (Elecsys® HBsAg II, Elecsys® Anti‐HCV II, Elecsys® HIV combi PT; Roche Diagnostics). Total anti‐HBc were tested on samples randomly selected using CMIA (Elecsys® Anti‐HBc II; Roche Diagnostics). HBV‐DNA and HCV‐RNA viral loads (VLs) were quantified respectively on HBsAg and anti‐HCV‐reactive samples using the Roche Molecular System (COBAS AmpliPrep/COBAS Taqman HBV Test Version 2.0; COBAS AmpliPrep/COBAS Taqman HCV Test Version 2.0). To detect possible occult hepatitis B infection, HBV‐DNA‐VL was quantified in HBsAg‐negative samples randomly selected (COBAS AmpliPrep/COBAS Taqman HBV Test Version 2.0). The manufacturer's reported limits of detection for HBsAg, HIV (p24 antigen), HBV DNA, and HCV RNA were 0.1 (0.88ng/ml), ≤2, 20, and 15 IU/ml, respectively. As for Elecsys® Anti‐HCV II, the sensitivity and specificity were 100% and 99.9%, respectively, and 100% for both for Elecsys® Anti‐HBc II. With respect to the cost of testing, serological markers have been estimated to cost approximately $7.00 per test, and approximately $25.00 for molecular testing. All tests were performed according to the manufacturer's instructions.

Sanou A.M., Nikièma A.S., Zalla S., Ouattara M., Dakouo N.P., Kiba‐Koumare A., Seynou M., Napon‐Zongo D, & Sombié R. (2022). Residual risk of hepatitis B virus transmission through blood donations in Burkina Faso screened with rapid diagnostic tests. Health Science Reports, 5(5), e748.

+ Open protocol

+ Expand

Cross-sectional HIV testing study

Check if the same lab product or an alternative is used in the 5 most similar protocols

Between 1 January and 31 December 2013, we conducted a cross-sectional study in eight NSW sites with high MSM caseloads (five public HIV or sexual health services, two general practices and one community clinic). Eligible participants were aged 18 years or older, consented to testing with one ORT plus a confirmatory fourth-generation EIA (either an Elecsys HIV Combi PT [Roche Diagnostics] or Architect HIV Ag/Ab Combo [Abbott Diagnostics] assay, depending on the local laboratory).

Chan D., Stewart M., Smith M., Price T., Lusk J., Ooi C., Read P, & Finlayson R. (2015). The rise of targeted HIV oral rapid testing in Australia. The Medical journal of Australia, 202(5).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!